InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain
InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
HLG
1.51%
33.5¢
HEDLEY LEISURE AND GAMING PROPERTY FUND - Corporate Spotlight
Currently unlisted.
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.